GHK-Cu boosted decorin mRNA, suppressed biglycan, and elevated chondroitin/dermatan sulfate in rat wounds
Background
Wound healing is a highly orchestrated process requiring precise remodeling of the extracellular matrix (ECM). Glycosaminoglycans (GAGs) and small leucine-rich proteoglycans such as decorin and biglycan are critical regulators of collagen fibrillogenesis and tissue repair, yet how individual ECM components are differentially regulated during wound closure remains poorly understood. GHK-Cu (glycyl-L-histidyl-L-lysine-Cu²⁺) is a naturally occurring tripeptide-copper complex already identified as a wound-healing activator, but its specific effects on proteoglycan gene expression and GAG composition had not been characterized systematically across temporal wound stages.
Study Design
Researchers used a rat subcutaneous wound-chamber model receiving repeated injections of glycyl-L-histidyl-L-lysine-Cu²⁺ at 2 mg per injection versus untreated controls, monitoring tissue production over 22 days (with key time-points at days 12 and 22). Primary endpoints included dry weight, total protein, hydroxyproline (type I collagen proxy), and uronic acid (GAG proxy). Electrophoretic analysis resolved individual GAG species. Northern blot quantified steady-state mRNA levels of decorin and biglycan. A parallel rat dermal fibroblast culture arm confirmed cell-autonomous effects of GHK-Cu on proteoglycan expression.
Results
GHK-Cu treatment stimulated wound tissue production as measured by increases in dry weight and total protein. Type I collagen synthesis rose, reflected by elevated hydroxyproline content, and total GAG output increased as shown by uronic acid measurements. Electrophoretic analysis revealed that chondroitin sulfate and dermatan sulfate accumulated progressively in control wound chambers while hyaluronic acid proportion declined over time; GHK-Cu treatment enhanced this accumulation of chondroitin sulfate and dermatan sulfate further.
GHK-Cu increased
decorinmRNA levels while simultaneously decreasingbiglycanmRNA levels in wound tissue — opposite directional regulation of two closely related small proteoglycans by the same compound.
In the temporal profile, biglycan mRNA peaked at day 12 then declined, whereas decorin mRNA rose progressively through day 22 in controls. In dermal fibroblast cultures, GHK-Cu reproduced the stimulation of decorin expression, confirming a cell-autonomous mechanism, but did not modify biglycan expression in vitro, suggesting the biglycan suppression observed in vivo may require additional tissue-level signals.
Key Findings
- GHK-Cu (2 mg/injection) increased wound dry weight, total protein, hydroxyproline, and uronic acid vs. controls
- Chondroitin sulfate and dermatan sulfate accumulation in wound chambers was enhanced by GHK-Cu treatment
- GHK-Cu increased
decorinmRNA and decreasedbiglycanmRNA in wound tissue — opposite directions BiglycanmRNA peaked at day 12;decorinmRNA rose progressively to day 22 in untreated wounds- GHK-Cu up-regulated
decorinin dermal fibroblast cultures but did not alterbiglycanexpression in vitro
Why It Matters
The divergent regulation of decorin versus biglycan by GHK-Cu has direct practical relevance: decorin is a negative regulator of TGF-β and is associated with reduced scarring and more organized collagen architecture, making its upregulation a desirable outcome in wound-care and anti-fibrotic protocols. Clinicians and formulators evaluating GHK-Cu for topical wound or scar applications now have mechanistic ECM data — not just gross healing metrics — to rationalize its use. Translation from rat subcutaneous chambers and primary fibroblast cultures to human dermal applications remains a significant step, but the conserved in vitro fibroblast finding strengthens the mechanistic case. Stacking GHK-Cu with decorin-pathway-augmenting agents (e.g., strategies that further suppress TGF-β-driven fibrosis) may be a rationale worth exploring in future protocols.
TitrateLab articles covering GHK-Cu
Written by TitrateLab, separately from the study summarized above.
